Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(6):e38559.
doi: 10.1371/journal.pone.0038559. Epub 2012 Jun 12.

Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients

Raquel Catarino  1 , Ana Coelho, António Araújo, Mónica Gomes, Augusto Nogueira, Carlos Lopes, Rui Medeiros
Affiliations

Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients

Raquel Catarino et al. PLoS One. 2012.

Abstract

Purpose: The purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease.

Methods: We conducted a study of 309 individuals and the cDNA levels were assessed through real-time PCR methodology.

Results: We found increased cDNA levels in NSCLC patients compared to control individuals. We also found a decreased overall survival time in patients presenting high cDNA levels, when compared to lower cDNA concentrations.

Conclusions: Quantification of cDNA may be a good tool for NSCLC detection with potential for clinical applicability.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Mean rank of cDNA plasma concentrations in pre-treatment NCLC patients and control individuals.
*Mann-Whitney U-test.
Figure 2
Figure 2. Receiver-operating characteristics (ROC) curve to calculate sensitivity and specificity of circulating plasma DNA as a tumor marker of NSCLC.
Figure 3
Figure 3. Cox regression analysis of overall survival according to cDNA levels, with tumor stage as covariate.
See this image and copyright information in PMC

References

    1. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 2009;64:92–97. - PubMed
    1. Sethi T. Lung cancer. Introduction. Thorax. 2002;57:992–993. - PMC - PubMed
    1. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–1057. - PubMed
    1. Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the natural history of nonsmall cell lung cancer (NSCLC)–comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer. 2006;106:2208–2217. - PubMed
    1. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654–1664. - PubMed

Publication types